ResMed Inc. (RMD) Financial Statements
Historical financial data — 44 statements covering FY2016–FY2026
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks, and accessories for the treatment of sleep apnea. Increasing diag...
ResMed Inc.'s revenue increased 9.9% year over year, from $5.15B to $5.65B.
Net income increased 8.8% over the same period, from $1.40B to $1.52B.
Over the 10-year period from FY2016 to FY2026, revenue grew by 207% in total.
Total debt increased by 23.6% to $825.9M.
The debt-to-equity ratio stands at 0.13, indicating a conservative leverage profile.
Operating cash flow grew 3.1% to $1.81B.
ResMed Inc. maintains a strong net profit margin of 26.9%.
Recent Financial Statements
Quarterly figures are standalone quarters, de-cumulated from YTD filings (Q4 = FY − Q3 YTD when not reported).
| Period | Revenue | Net Income | Gross Profit | EBIT | Op. Cash Flow | Total Assets | Total Debt | Equity |
|---|---|---|---|---|---|---|---|---|
| Q1 FY2025 | $1.22B+0.1% | $311.4M | $717.2M | $387.3M | $325.5M | $7.22B | $677.5M | $5.20B |
| Q2 FY2025 | $1.28B+4.7% | $344.6M | $751.3M | $417.2M | $308.6M | $7.14B | $672.8M | $5.25B |
| Q3 FY2025 | $1.29B+0.8% | $365.0M | $766.4M | $426.3M | $578.7M | $7.57B | $673.0M | $5.55B |
| Q4 FY2025 | $1.35B+4.4% | $379.7M | $820.1M | $454.5M | $538.8M | $8.17B | $668.3M | $5.97B |
| Q1 FY2026 | $1.34B-0.9% | $348.5M | $820.8M | $446.5M | $457.3M | $8.31B | $668.6M | $6.12B |
| Q2 FY2026 | $1.42B+6.5% | $392.6M | $878.7M | $491.7M | $339.7M | $8.50B | $663.8M | $6.32B |
| Q3 FY2026 | $1.43B+0.6% | $398.7M | $891.0M | $499.8M | $554.1M | $8.78B | $843.2M | $6.49B |
| Q4 FY2026 | $1.46B+2.3% | $383.4M | $861.2M | $448.7M | $454.6M | $8.97B | $825.9M | $6.59B |
Balance Sheet Summary (FY2026)
ResMed Inc. (RMD) Financial Statements & Revenue History
ResMed Inc. (RMD) is a US-listed stock operating in the Healthcare sector, specifically the Surgical & Medical Instruments & Apparatus industry trading at $238.97 with a market capitalization of $34. This page provides 44 historical financial statements for ResMed Inc., including income statement, balance sheet, and cash flow data across multiple reporting periods. Most recently, ResMed Inc. reported revenue of $5.7 billion, representing 9.9% year-over-year growth. The net profit margin of 26.9% reflects strong profitability. The debt-to-equity ratio of 0.13 shows conservative leverage.
RMD Income Statement, Balance Sheet & Cash Flow
The financial statements table above shows ResMed Inc.'s revenue, net income, gross profit, EBIT, operating cash flow, total assets, total debt, and shareholders' equity across the most recent reporting periods. Year-over-year growth rates help identify whether RMD is accelerating or decelerating in terms of top-line revenue and bottom-line profitability.
- Revenue trend: Track RMD's top-line growth across quarters and fiscal years to identify acceleration or deceleration in the business.
- Profitability: Net income and gross profit margins reveal how efficiently ResMed Inc. converts revenue into earnings.
- Balance sheet health: Total assets, liabilities, debt, and equity provide a snapshot of RMD's financial position and leverage.
- Cash flow: Operating cash flow shows how much cash the business generates from its core operations, which is critical for funding dividends, buybacks, and growth.
How to Use RMD Financial Data
Investors use ResMed Inc.'s financial statements to assess the company's financial health, growth trajectory, and valuation. Key metrics to focus on include:
- Revenue growth rate: Consistent double-digit revenue growth suggests a strong business; declining revenue may signal competitive pressure.
- Net profit margin: Higher margins indicate a more efficient business with pricing power. Compare RMD's margins to sector peers for context.
- Debt levels: High debt-to-equity ratios increase financial risk, especially in rising-rate environments. Low debt provides flexibility.
- Valuation multiples: See how RMD's P/E, P/S, and EV/EBITDA ratios compare to historical levels.
- Full analysis: View RMD's financial health score, earnings, and pre-market pricing.
Financial data is sourced from ResMed Inc.'s SEC filings (10-K, 10-Q) via Polygon.io and Finnhub.RMD trades on NYSE/NASDAQ. This page is for informational purposes only and is not financial advice.